HPS Pharmacies wish to give notice that Alphapharm is experiencing a supply interruption for dicloxacillin capsules as follows:
|Product||Strength||ARTG||Expected Return Date|
|Distaph®||250mg||226506||1st July 2019|
|Distaph®||500mg||226508||1st July 2019|
|Dicloxacillin Mylan||250mg||289105||1st July 2019|
|Dicloxacillin Mylan||500mg||289107||1st July 2019|
Supplies are expected to return to normal in early July 2019. There are currently no alternative preparations available.
Dicloxacillin is a narrow-spectrum penicillin antibiotic indicated for the treatment of staphylococcal and other Gram positive coccal infections such as cellulitis, osteomyelitis, wound infections, and pneumonia. It has a similar spectrum of activity to flucloxacillin which may be considered as an alternative. Both dicloxacillin and flucloxacillin are resistant to staphylococcal penicillinase but are inactive against methicillin-resistant Staphylococcus aureus (MRSA). Benzylpenicillin provides greater activity against Streptococcus pneumoniae and Streptococcus pyogenes and is preferred for the treatment of streptococcal pneumonia. The appropriate product information should be consulted for further information and the advice of an Infectious Disease Physician sought for individual cases.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Alphapharm on 1800 274 276.
1. Antibiotic Expert Group. Therapeutic Guidelines: Antibiotic (ver 15). Melbourne: Therapeutic Guidelines; 2014.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates